Toll-Like Receptors and the Response to Radiotherapy in Solid Tumors: Challenges and Opportunities

Area of Science:

• Immunology
• Oncology
• Radiotherapy

Background:

• Toll-like receptors (TLRs) are key regulators of innate and adaptive immunity, recognizing pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs).
• TLR agonists are investigated for cancer vaccines and combined with immunotherapy, chemotherapy, and radiotherapy (RT).
• The role of TLRs in cancer is complex, with potential roles in tumor progression or apoptosis, and their interaction with RT is not fully understood.

Purpose of the Study:

• To review the multifaceted role of TLR signaling in cancer, particularly in response to radiation therapy.
• To elucidate the mechanisms by which radiation influences TLR pathways.
• To provide a framework for designing effective TLR-based therapeutic strategies in conjunction with RT.

Main Methods:

• Literature review of studies investigating TLRs in cancer and their response to radiation therapy.
• Analysis of mechanisms of TLR activation by radiation, both direct and indirect.
• Synthesis of current knowledge on TLR agonists in clinical trials with RT.

Main Results:

• Radiation can directly stimulate TLR pathways or indirectly activate them through radiation-induced cell damage.
• TLR signaling can exert both pro-tumoral and anti-tumoral effects in response to RT, influenced by factors like radiation dose, fractionation, and host genetics.
• Several TLR agonists are in clinical trials, often combined with standard treatments like RT.

Conclusions:

• TLR signaling significantly influences tumor response to radiation therapy.
• Understanding TLRs' complex roles is crucial for optimizing cancer treatment strategies.
• Targeting TLRs in combination with RT holds promise for novel cancer therapies.